论文部分内容阅读
全球慢性乙型肝炎感染者多达3.6亿,我国占1.2亿,慢性HBV感染者中的50%~75%有活跃的病毒复制和肝脏炎症改变,目前未有令人满意的治疗方法。在临床实践中,近期治疗目标是减轻肝脏炎症、预防肝纤维化和肝功能失代偿。古拉定作为一种抗氧化剂,能够减少自由基对肝细胞膜的损害,从而
There are as many as 360 million people with chronic hepatitis B infection in our country and 120 million people in our country. Between 50% and 75% of those with chronic HBV infection have active virus replication and hepatic inflammation, and there is no satisfactory treatment. In clinical practice, the recent treatment goal is to reduce liver inflammation, prevent liver fibrosis and decompensation of liver function. Goodola as an antioxidant, can reduce the damage of free radicals on the liver cell membrane, thus